Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- ...

The use of oral vancomycin prophylaxis was associated with a significant decrease in the recurrence of Clostridium difficile infection, according to a poster presentation at the Interscience ...

Preventative oral vancomycin reduces the incidence of C. difficle during allogeneic hematopoietic stem cell transplantation, according to a study by Pittsburgh-based University of Pennsylvania ...

Clostridioides difficile (C. difficile) is a leading cause of illness and death, especially for frail and hospitalized Americans. Now, a new study suggests that the leading antibiotic used to fight it ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

Fecal microbiota transplant might be considered for first-line treatment of Clostridioides difficile (C. diff), based on noninferiority findings from a randomized, open-label trial. A similar ...

Fidaxomicin should be the antibiotic of choice when treating adults with Clostridioides difficile infection, according to new guidance from the Infectious Diseases Society of America and the Society ...

The combination of vancomycin and fecal microbiota transplantation was found to be superior to fidaxomicin or vancomycin in the treatment of patients with recurrent Clostridioides (formerly ...

A study has linked initial vancomycin monotherapy to higher rates of Clostridium difficile infection in patients with inflammatory bowel disease, according to a report by Internal Medicine News. The ...

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...

April 4, 2012 (London, United Kingdom) — Fidaxomicin (Dificid, Optimer Pharmaceuticals) treatment was superior to vancomycin for initial cure, recurrence, and sustained response, according to a ...

Clostridium difficile is the most common cause of nosocomial diarrhea in acute-care settings. Until now, the two available therapies for C. difficile-associated diarrhea (CDAD), vancomycin and ...